



Synlogic Joins Russell 3000® Index

June 25, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 25, 2018-- Synlogic, Inc. ([Nasdaq: SYBX](#)), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the company's addition to the Russell 3000® Index, following the Russell US Indices' annual reconstitution, effective Monday, June 25, 2018.

"We are pleased to benchmark Synlogic's growth with our addition to the Russell 3000 Index, which offers a platform to increase the company's visibility and exposure to leading institutional investors," said Aoife Brennan, M.B., B.Ch., Synlogic's interim president and chief executive officer and chief medical officer.

Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indices. FTSE Russell determines membership for its Russell US Indices primarily by objective, market-capitalization rankings and style attributes. Russell US Indices are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately \$9 trillion in assets are benchmarked against Russell US Indices. Russell US Indices are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000® Index and the Russell US Indices' reconstitution, go to the "Russell Reconstitution" section on the [FTSE Russell website](#).

About Synlogic

Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The company's two lead programs, SYNB1020 and SYNB1618, target hyperammonemia as a result of liver damage or genetic disease, and PKU, respectively. When delivered orally, Synthetic Biotic medicines can act from the gut to compensate for the dysfunctional metabolic pathway and have a systemic effect, with the potential to significantly improve symptoms of disease for affected patients. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism, liver disease, inflammatory and immune disorders, and cancer; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; the potential of Synlogic's technology to treat hyperammonemia and phenylketonuria; and the expected timing of Synlogic's anticipated clinical trial initiations. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180625005257/en/>

Source: Synlogic, Inc.

MEDIA:

Synlogic

Courtney Heath, 617-872-2462

courtney@scientpr.com

or

INVESTORS:

Synlogic

Elizabeth Wolffe, Ph.D., 617-207-5509

liz@synlogictx.com

